Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Enters into Agreement with Bradley L. Radoff and Michael Torok BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious